BioSpace News Archive

REGENXBIO Inc. (Nasdaq: RGNX) today announced its intention to file a Biologics License Application (BLA) in 2024 using the FDA’s accelerated approval pathway for RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome.

Castle Biosciences, Inc. today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity 42 nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern time.

AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company.

Seres Therapeutics, Inc. today reported second quarter 2022 financial results and provided business updates.

Senseonics Holdings, Inc. today announced that Anthem is providing coverage for implantable CGM, which includes the Eversense® CGM System.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Eyam Vaccines and Immunotherapeutics (Eyam), has announced a new licensing agreement for innovative vaccine technologies from the University of British Columbia (UBC), and the James Hutton Institute (JHI).

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has secured a significant order for OxC-beta™ from AB Vista.

Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2022 and provided a business update.

HCW Biologics Inc. (the “Company”) NASDAQ: HCWB), was granted U.S. Patent 11,401,324 which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains on a scaffold made of an extracellular domain of human tissue factor.